These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 32198945)

  • 21. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults.
    Samrao A; Berry TM; Goreshi R; Simpson EL
    Arch Dermatol; 2012 Aug; 148(8):890-7. PubMed ID: 22508772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
    Sobell JM; Foley P; Toth D; Mrowietz U; Girolomoni G; Goncalves J; Day RM; Chen R; Yosipovitch G
    Acta Derm Venereol; 2016 May; 96(4):514-20. PubMed ID: 26837052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Familial "benign" pemphigus? Erythroderma and fatal outcome.
    Tansini PB; Boff AL; Weber MB; Bonamigo RR
    An Bras Dermatol; 2020; 95(1):75-77. PubMed ID: 31959512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Benign familial chronic pemphigus (Hailey-Hailey disease). Treatment with carbon dioxide laser].
    Pissoat L; Höller Obrigkeit D
    Hautarzt; 2010 May; 61(5):376-8. PubMed ID: 20390242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful botulinum toxin (onabotulinumtoxinA) treatment of Hailey-Hailey disease.
    Ho D; Jagdeo J
    J Drugs Dermatol; 2015 Jan; 14(1):68-70. PubMed ID: 25607910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apremilast (otezla) for psoriatic arthritis.
    Med Lett Drugs Ther; 2014 May; 56(1443):41-2. PubMed ID: 24869713
    [No Abstract]   [Full Text] [Related]  

  • 27. Aminoglycosides as potential pharmacogenetic agents in the treatment of Hailey-Hailey disease.
    Kellermayer R; Szigeti R; Keeling KM; Bedekovics T; Bedwell DM
    J Invest Dermatol; 2006 Jan; 126(1):229-31. PubMed ID: 16417242
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety evaluation of apremilast for the treatment of psoriasis.
    Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
    Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apremilast for the management of moderate to severe plaque psoriasis.
    Vangipuram R; Alikhan A
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata.
    Sakakibara M; Shimoyama H; Nomura M; Nakashima C; Hirabayashi M; Sei Y; Kuwano Y
    Eur J Dermatol; 2019 Aug; 29(4):436-437. PubMed ID: 31625923
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis.
    Baughman RP; Judson MA; Ingledue R; Craft NL; Lower EE
    Arch Dermatol; 2012 Feb; 148(2):262-4. PubMed ID: 22004880
    [No Abstract]   [Full Text] [Related]  

  • 32. Three cases of palmoplantar pustulosis successfully treated with apremilast.
    Eto A; Nakao M; Furue M
    J Dermatol; 2019 Jan; 46(1):e29-e30. PubMed ID: 29905386
    [No Abstract]   [Full Text] [Related]  

  • 33. Hailey-Hailey disease patient with a novel missense mutation in ATP2C1 successfully treated with minocycline hydrochloride.
    Shigehara Y; Shinkuma S; Fujimoto A; Saijo S; Abe R
    J Dermatol; 2018 Nov; 45(11):e306-e308. PubMed ID: 29740863
    [No Abstract]   [Full Text] [Related]  

  • 34. Psoriasis improvement and satisfaction in patients using a clobetasol spray and oral apremilast combination regimen: A pilot study.
    Wei C; Friedman AJ; Prussick RB
    J Am Acad Dermatol; 2020 Oct; 83(4):1198-1200. PubMed ID: 32088274
    [No Abstract]   [Full Text] [Related]  

  • 35. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
    J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing the Risk of Apremilast Use for Psoriasis During the COVID-19 Pandemic.
    Kearns DG; Uppal S; Chat VS; Wu JJ
    J Drugs Dermatol; 2021 May; 20(5):582-583. PubMed ID: 33938697
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.
    Pathan E; Abraham S; Van Rossen E; Withrington R; Keat A; Charles PJ; Paterson E; Chowdhury M; McClinton C; Taylor PC
    Ann Rheum Dis; 2013 Sep; 72(9):1475-80. PubMed ID: 22984171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hailey-Hailey disease: the role of azathioprine an immunomodulator.
    Malan M; Xuejingzi W; Si J; Quan SJ
    Pan Afr Med J; 2019; 32():65. PubMed ID: 31223357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
    Gottlieb AB; Matheson RT; Menter A; Leonardi CL; Day RM; Hu C; Schafer PH; Krueger JG
    J Drugs Dermatol; 2013 Aug; 12(8):888-97. PubMed ID: 23986162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world use of apremilast for patients with psoriasis in Japan.
    Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.